Frontiers in Psychiatry
2024
Alexandros Matsingos, Marcel Wilhelm, Laila Noor et al.
18 citations
Ketamine and esketamine offer a novel approach in the pharmacological treatment of major depressive disorder (MDD). This meta-analysis aimed to investigate the placebo response in double-blind, randomized controlled studies (RCTs) on patients with MDD receiving ketamine or esketamine. For this systematic review and meta-analysis Medline (PubMed), Cochrane Central Register of Controlled Trials...
Frontiers in Pharmacology
2024
Senbing Zhang, Yanzhu Pu, Jianning Liu et al.
12 citations
(R, S)- and (S)-ketamine have made significant progress in the treatment of treatment-resistant depression (TRD) and have become a research focus in recent years. However, they both have risks of psychomimetic effects, dissociative effects, and abuse liability, which limit their clinical use. Recent preclinical and clinical studies have shown that (R)-ketamine has a more efficient and lasting...
Frontiers in Psychiatry
2024
Michael Bayrhammer-Savel, Martin Ortner, Marie Claire Van Hout et al.
6 citations
The fundamental right to equivalence of health care in prison settings encompasses the provision of medication to address mental health conditions. Considering the increased risk for self-harm among individuals dealing with depression, the limited effectiveness of conservative antidepressants is a major challenge in psychiatry. The high prevalence of suicidal tendencies within prison...
Frontiers in Psychiatry
2024
Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki et al.
4 citations
Borderline personality disorder (BPD) is diagnosed in 10-30% of patients with major depressive disorder (MDD), and the frequency of MDD among individuals with BPD reaches over 80%. The comorbidity of MDD and BPD is associated with more severe depressive symptoms and functional impairment, higher risk of treatment resistance and increased suicidality. The effectiveness of ketamine usage in...
Neuropsychiatric Disease and Treatment
2024
Xuemeng Chen, Rui Zhou, Lan Lan et al.
4 citations
Major depressive disorder (MDD) is a common mood disorder. Electroconvulsive therapy (ECT) has a significant effect on treatment-resistant MDD. Esketamine may have potential advantages in improving the efficacy of ECT, and the strong affinity of this compound for NMDAR renders it a viable therapeutic option for the management of depression. This study aims to compare the effects of different...
Frontiers in Psychiatry
2024
Haixia Chen, Xinxin Zhao, Xinxu Ma et al.
9 citations
Mounting evidence has identified the rapid and sustained antidepressive and anxiolytic-like effects of esketamine. However, the underlying mechanism of this no-monoamine target rapid-onset antidepressant is still underexplored. Immune-inflammatory pathways and cell-mediated immune activation, mainly including inflammatory cytokines in plasma, play a pivotal role in the pathogenesis of major...
Frontiers in Psychiatry
2024
Matteo Di Vincenzo, Vassilis Martiadis, Bianca Della Rocca et al.
31 citations
Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many...
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
2024
D V Kurkin, E I Morkovin, D A Bakulin et al.
Depression is a leading cause of disability and reduced work capacity worldwide. The monoamine theory of the pathogenesis of depression has remained dominant for many decades, however, drugs developed on its basis have limited efficacy. Exploring alternative mechanisms underlying this pathology could illuminate new avenues for pharmacological intervention. Targeting glutamatergic pathways in...
Case Reports in Psychiatry
2024
Jai Ahuja, Luba Leontieva
This case report examines the unexpected increase in suicidal ideation following ketamine infusion therapy in a 75-year-old female with a history of treatment-resistant depression. Despite ketamine's established efficacy in treating depression and acute suicidality, this patient's condition deteriorated posttreatment. The report delves into the patient's complex background, including...
Frontiers in Pharmacology
2024
Ruixue Liu, Chunxiao Liu, Dianwei Feng et al.
5 citations
Esketamine nasal spray (ESK-NS) is a new drug for treatment-resistant depression, and we aimed to detect and characterize the adverse events (AEs) of ESK-NS using the Food and Drug Administration (FDA) adverse event reporting system (FAERS) database between 2019 Q1 and 2023 Q4. Reporting odds ratio (ROR), proportional reporting ratio (PRR), and multi-item gamma Poisson shrinker (MGPS) were...